NexImmune Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 62
Employees
  • Stock Symbol
  • NEXI
Stock Symbol
  • Share Price
  • $2.24
  • (As of Monday Closing)

NexImmune General Information

Description

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Contact Information

Website
www.neximmune.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 9119 Gaither Road
  • Gaithersburg, MD 20877
  • United States
+1 (301) 000-0000

NexImmune Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NexImmune Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.24 $2.47 $2.20 - $26.50 $56.1M 22.7M 78.4K -$2.72

NexImmune Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 240,636
Revenue 0 0 0 0
EBITDA (40,775) (27,585) (20,357) (12,901)
Net Income (43,387) (29,866) (20,547) (12,834)
Total Assets 104,542 11,301 13,718 14,142
Total Debt 0 19,118 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NexImmune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NexImmune‘s full profile, request access.

Request a free trial

NexImmune Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore NexImmune‘s full profile, request access.

Request a free trial

NexImmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells
Biotechnology
Gaithersburg, MD
62 As of 2021
00000
0000 0000-00-00
00000000 00000

0000 000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000 000000000
Redwood City, CA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
San Carlos, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NexImmune Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bolt Biotherapeutics Venture Capital-Backed Redwood City, CA 00 00000 00000000 00000
0000000 0000000000 Corporation San Carlos, CA 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 Formerly VC-backed New Haven, CT 000 00000 000000 - 000 00000
You’re viewing 5 of 61 competitors. Get the full list »

NexImmune Patents

  • 30

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

NexImmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019375997-A1 T cell compositions with improved phenotypic properties Pending 08-Nov-2018 000000000
CA-3118757-A1 T cell compositions with improved phenotypic properties Pending 08-Nov-2018 000000000
US-20200215115-A1 T cell compositions with improved phenotypic properties Granted 08-Nov-2018 00000000000
US-20200188435-A1 T cell compositions with improved phenotypic properties Pending 08-Nov-2018 00000000000
US-11007222-B2 T cell compositions with improved phenotypic properties Active 08-Nov-2018 A61K39/0011 00
To view NexImmune’s complete patent history, request access »

NexImmune Executive Team (11)

Name Title Board Seat Contact Info
Kristi Jones Chief Executive Officer & Board Member
John Trainer Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Mathias Oelke Ph.D Scientific Co-Founder, Senior Vice President, Preclinical Immunotherapy & Head of Cell Biology
Daniel Bednárik Ph.D Senior Vice President, Molecular Engineering & Protein Design
Robert Knight Chief Medical Officer
You’re viewing 5 of 11 executive team members. Get the full list »

NexImmune Board Members (16)

Name Representing Role Since
Alan Roemer Self Board Member 000 0000
Grant Verstandig Self Board Member 000 0000
Kristi Jones NexImmune Chief Executive Officer & Board Member 000 0000
Paul D'Angio NexImmune Board Member 000 0000
Robert Spiegel MD Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

NexImmune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NexImmune Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NexImmune‘s full profile, request access.

Request a free trial